Highlights
- Dr Reddy's Laboratories (NSE:DRREDDY) closed 5.77 per cent lower on Thursday, 9 July 2026, the steepest fall on the Nifty 50.
- The company said certain batches of its diabetes and weight-management drug semaglutide did not meet specifications, tracing the issue to the active pharmaceutical ingredient.
- Commercial supplies of semaglutide will be delayed while an investigation is completed; the company said patient safety has not been affected.
- The slide, the stock's worst in about three years, erased an estimated Rs 6,585 crore in market value, with the shares touching a low of Rs 1,261.20 intraday.
Dr Reddy's Laboratories (NSE:DRREDDY) suffered its sharpest single-day fall in about three years on Thursday, 9 July 2026, after the drugmaker disclosed that certain batches of semaglutide, its diabetes and weight-management product, failed to meet specifications. The stock slid as much as 6.49 per cent intraday to Rs 1,261.20 on the NSE and closed 5.77 per cent lower, making it the biggest loser on the Nifty 50 in a session where the index itself gained 0.34 per cent.
In its exchange filing, the Hyderabad-based company traced the problem to the active pharmaceutical ingredient, the core raw material used in manufacturing the drug. As a consequence, commercial supplies of semaglutide will be delayed while an investigation is carried out. The company stated that patient safety has not been affected. The sell-off wiped out an estimated Rs 6,585 crore of market capitalisation.
Why investors reacted sharply
Semaglutide sits at the centre of one of the most closely watched opportunities in Indian pharma: the anti-obesity and diabetes market opened up by the molecule's patent expiry in several geographies. A quality issue at the API stage, rather than at final formulation, raised questions about the timeline for a full commercial ramp-up. With market expectations built around an early and smooth launch trajectory, even a temporary supply delay carried outsized weight for the stock.
Market context
The fall stood out against a firm market backdrop. The Sensex rose 238.22 points to 76,741.82 and the Nifty 50 added 80.75 points to 23,962.80 on Thursday, while the Nifty Pharma index actually gained 0.89 per cent, aided by a 2.78 per cent rise in Sun Pharmaceutical Industries (NSE:SUNPHARMA), the day's top Nifty gainer. The divergence underscored that the pressure on Dr Reddy's was entirely company-specific rather than sectoral.
What market participants will monitor
The immediate focus is the outcome and duration of the company's investigation into the API issue, followed by a revised timeline for commercial semaglutide supplies. Any communication from regulators, remediation steps at the ingredient supplier level, and the impact on near-term revenue guidance when the company reports its Q1 FY27 results will all be scrutinised. Commentary on whether existing distributed batches are affected is another point of attention, although the company has indicated no patient-safety impact.
Peer perspective
Several Indian drugmakers are positioned in the semaglutide opportunity, including Sun Pharmaceutical Industries, Cipla (NSE:CIPLA), Lupin (NSE:LUPIN) and Natco Pharma (NSE:NATCOPHARM), and any slippage by one participant tends to be read against the launch readiness of the others. Thursday's session offered a case in point, with Sun Pharma rallying even as Dr Reddy's fell. Execution on quality and supply chains is emerging as the key differentiator in this segment.
The road ahead
Dr Reddy's has moved quickly to disclose the issue and frame it as a supply-timing matter rather than a safety event. The stock's reaction, however, shows how tightly the market is tracking every step of the semaglutide rollout. Clarity on the investigation and a firm resupply schedule are now the milestones that will shape sentiment in the counter.
FAQs
Q: Why is the company in focus today?
A: Dr Reddy's fell 5.77 per cent on 9 July 2026, its worst session in about three years, after disclosing that certain semaglutide batches did not meet specifications. The issue was traced to the active pharmaceutical ingredient and will delay commercial supplies.
Q: What factors are investors monitoring?
A: Attention centres on the investigation's outcome, a revised supply timeline for semaglutide, and any regulatory communication. The impact on near-term earnings and commentary at the Q1 FY27 results are also being tracked.
Q: Which peer companies are relevant?
A: Sun Pharmaceutical Industries (NSE:SUNPHARMA), Cipla (NSE:CIPLA), Lupin (NSE:LUPIN) and Natco Pharma (NSE:NATCOPHARM) are relevant peers with interests in the semaglutide opportunity. Sun Pharma rose 2.78 per cent in the same session, highlighting the company-specific nature of the fall.
Q: Is this article investment advice?
A: No. This article is intended solely for informational purposes and should not be considered investment, financial or trading advice.